从长春长生疫苗事件谈我国假劣药法律界定之完善
DOI:
CSTR:
作者:
作者单位:

1.南京医科大学药学院;2.南京医科大学医政学院

作者简介:

通讯作者:

中图分类号:

基金项目:


Discussion on the Definition of Adulterated Drug and Misbranded Drug in Drug Management Law based on the event of Changchun Changsheng’s Adulterated Vaccine
Author:
Affiliation:

1.School of Pharmacy, School of Health Policy and Management,Nanjing Medical University;2.School of Health Policy and Management, Nanjing Medical University

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    本文通过分析长春长生疫苗事件中不合格疫苗的法律定性,揭示我国现行药品法在假劣药界定中存在的不科学、不合理的问题,并结合我国《刑法》对生产销售假劣药行为的刑事责任的具体规定,阐述长生疫苗事件中不合格疫苗在定性和刑事责任判定上面临的困境。围绕长生疫苗案件中的焦点问题,借鉴美国药事法律对不合格药品的划分,提出应科学界定假药的概念、将是否遵守《药品生产质量管理规范》作为判定假药的标准之一,并加大对违法制售假疫苗行为的刑事处罚力度。

    Abstract:

    By analyzing the legal qualification of unqualified vaccines in Changchun Changsheng’s vaccine event, this paper revealed unscientific and unreasonable problems in the definition of counterfeit and inferior medicines in current drug laws of China. In addition, combined with the specific provisions of Criminal Law on the criminal responsibility for the production and sale of counterfeit and inferior medicines, this paper elaborated the dilemma faced by unqualified vaccines in judgment of qualitative and criminal responsibility in this event. Meanwhile, the paper focused on the focal problems in this event and drew on the classification of unqualified drugs by American Pharmaceutical Law. Finally, it proposed the concept that counterfeit drugs should be defined scientifically and whether to comply with the GMP should be as one of the criteria for determining counterfeit drugs, and to increase criminal penalties for illegal production and sale of fake vaccines.

    参考文献
    相似文献
    引证文献
引用本文
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2018-09-19
  • 最后修改日期:2018-09-19
  • 录用日期:2019-03-14
  • 在线发布日期:
  • 出版日期:
文章二维码